Report Description Table of Contents Introduction And Strategic Context The Global Tremfya (Guselkumab) Market is forecast to expand at a CAGR of 9.1%, valued at USD 3.1 billion in 2024 and reaching nearly USD 5.8 billion by 2030, driven by plaque psoriasis treatment demand, biologic drug innovation, immunology pipeline growth, specialty drug market, and autoimmune disease therapies, as estimated by Strategic Market Research. Tremfya, developed by Janssen Pharmaceuticals under Johnson & Johnson, is the first selective IL-23p19 inhibitor approved for moderate-to-severe plaque psoriasis and psoriatic arthritis. Its mechanism of action offers a more targeted approach than earlier biologics, leading to higher treatment durability and reduced dosing frequency, which strengthens patient adherence. Several macro forces are shaping the market between 2024 and 2030. Autoimmune disorders such as psoriasis are increasing globally, and biologics are steadily gaining adoption as frontline treatments over conventional systemic therapies. Regulatory agencies in major markets like the U.S., Europe, and Japan are approving new indications for Tremfya, widening its addressable patient base. At the same time, reimbursement reforms and payer alignment are creating broader access, especially in developed regions. From a stakeholder perspective, pharmaceutical companies, healthcare providers, payers, regulators, and patient advocacy groups all influence the adoption landscape. Physicians are central to prescription decisions, while payers determine formulary placement and pricing access. Patient groups continue to push for better awareness and access to advanced biologics, particularly in underpenetrated markets across Asia and Latin America. Tremfya is also strategically positioned within the competitive landscape. While it faces rivalry from other IL-23 inhibitors and oral small molecules, its unique dosing schedule and long-term safety data make it a strong choice for physicians seeking durable disease control. The brand’s growth trajectory will depend not only on Janssen’s commercial execution but also on how the biologics market evolves with biosimilar entries and new immunology innovations. In short, Tremfya is more than a psoriasis therapy. It reflects the broader shift toward precision biologics in autoimmune care, where patient demand, regulatory support, and innovation are converging to reshape treatment pathways over the forecast period. Comprehensive Market Snapshot The Global Tremfya (Guselkumab) Market is forecast to expand at a 9.1% CAGR, rising from USD 3.1 billion in 2024 to nearly USD 5.8 billion by 2030. USA Tremfya (Guselkumab) Market (83.5% share) is estimated at USD 2.59 billion in 2024 and, growing at an 8% CAGR, is projected to reach approximately USD 4.11 billion by 2030. Europe Tremfya (Guselkumab) Market (6% share) is estimated at USD 0.19 billion in 2024 and, advancing at a 6.9% CAGR, is expected to reach approximately USD 0.28 billion by 2030. APAC Tremfya (Guselkumab) Market (2% share) is estimated at USD 0.06 billion in 2024 and, expanding at a strong 11.3% CAGR, is projected to reach approximately USD 0.12 billion by 2030. Regional Insights USA accounted for the largest market share of 83.5% in 2024, driven by high biologic adoption rates, strong reimbursement frameworks, and large treated psoriasis populations. APAC is expected to expand at the fastest CAGR of 11.3% during 2024–2030, supported by biologics penetration, improving specialty access, and growing awareness of immune-mediated diseases. By Product Type Injectable Biologic (Subcutaneous) held the entire market share of 100% in 2024, as the therapy is currently commercialized exclusively in subcutaneous biologic format, representing approximately USD 3.1 billion of the global market. Long-Acting Subcutaneous Biologic Formulations are projected to grow at a notable CAGR during 2024–2030, supported by patient preference for eight-week maintenance dosing schedules and improved treatment adherence. By Application Plaque Psoriasis accounted for the largest share of 58% in 2024, reflecting its broader diagnosed population and established dermatology prescribing trends, corresponding to approximately USD 1.80 billion of the global market. Psoriatic Arthritis represented 42% of the market in 2024, valued at approximately USD 1.30 billion, and is expected to grow at a strong CAGR during 2024–2030 driven by rising rheumatology adoption and expansion into moderate-to-severe patient segments. Pipeline (Crohn’s Disease & Ulcerative Colitis – Under Study) held 0% commercial share in 2024, reflecting no marketed revenue contribution, although the segment presents future revenue potential post-regulatory approval. By Distribution Channel Specialty Pharmacies dominated the market with a 45% share in 2024, supported by cold-chain logistics, reimbursement coordination, and biologic dispensing expertise, translating to approximately USD 1.40 billion. Hospital Pharmacies accounted for 30% of the market in 2024, corresponding to approximately USD 0.93 billion, driven by institutional procurement and inpatient biologic administration. Retail & Specialty Pharmacies contributed 20% share in 2024, valued at approximately USD 0.62 billion, reflecting outpatient biologic distribution through specialty networks. Online Pharmacies represented 5% of the global market in 2024, equivalent to approximately USD 0.16 billion, and are forecast to grow at the highest CAGR during 2024–2030, particularly across Asia-Pacific and digitally advanced healthcare systems. Strategic Questions Guiding the Evolution of the Global Tremfya (Guselkumab) Market What specific indications, formulations, dosing regimens, and geographic markets are explicitly included within the Global Tremfya (Guselkumab) Market, and which potential pipeline uses remain out of scope? How does the Tremfya market structurally differ from broader psoriasis biologics, IL-17 inhibitors, TNF inhibitors, and other immunology-driven therapeutic markets? What is the current and forecasted size of the Global Tremfya Market, and how is revenue distributed across the USA, Europe, APAC, and other regions? How is revenue allocated between plaque psoriasis and psoriatic arthritis indications, and how is this mix expected to evolve through 2030? Which indication segment—dermatology (plaque psoriasis) or rheumatology (psoriatic arthritis)—is expected to generate the fastest incremental revenue growth? Which patient segments (biologic-naïve vs biologic-experienced, moderate vs severe disease) contribute disproportionately to revenue and margin expansion? How does demand differ across mild, moderate, and severe psoriasis populations, and how does this affect Tremfya’s positioning in treatment algorithms? How is Tremfya positioned within first-line, second-line, and advanced biologic therapy pathways compared to IL-17 and TNF inhibitors? What impact do treatment persistence, dosing frequency (every 8 weeks), and switching patterns have on annualized revenue per patient? How are disease prevalence trends, diagnosis rates, and specialist access influencing regional adoption patterns for Tremfya? What clinical trial outcomes, safety data, or comparative efficacy evidence influence payer and physician confidence in Tremfya? How do pricing pressure, rebate structures, formulary placement, and reimbursement policies affect net revenue realization in the USA and Europe? How strong is Tremfya’s expansion pipeline (Crohn’s disease, ulcerative colitis), and what revenue upside could additional approvals generate? Will new indications expand the total treated population or intensify competition within the IL-23 inhibitor segment? How do formulation stability, subcutaneous delivery, and long dosing intervals enhance adherence and long-term patient retention? How will patent timelines and eventual loss of exclusivity impact competitive dynamics in the post-2030 period? What role could future IL-23 biosimilars play in price erosion, market access expansion, and margin compression? How are leading competitors in the IL-23 and IL-17 classes positioning their portfolios to defend or capture share from Tremfya? Which geographic markets (USA, Europe, APAC) are expected to outperform global growth, and what structural factors drive that outperformance? How should manufacturers and investors prioritize indication expansion, geographic focus, and lifecycle management strategies to maximize long-term value in the Global Tremfya (Guselkumab) Market? Tremfya (Guselkumab) Market - Segment-Level Insights and Market Structure The Tremfya (Guselkumab) Market is defined by its biologic positioning within immune-mediated inflammatory disorders and its expanding clinical footprint across dermatology and rheumatology. As a monoclonal antibody targeting interleukin-23 (IL-23), Tremfya occupies a differentiated niche in long-term inflammatory disease control. Market segmentation reflects variations in administration format, disease application, and distribution pathways, each influencing adoption patterns, prescribing dynamics, and revenue concentration. The structure of this market is shaped by chronic treatment duration, specialty prescribing, payer authorization frameworks, and increasing movement toward specialty pharmacy fulfillment models. Product Type Insights: Injectable Biologic (Subcutaneous) Tremfya is positioned as a subcutaneous injectable biologic, administered at defined dosing intervals following induction. This delivery format influences both patient experience and distribution logistics. From a structural standpoint, the subcutaneous route offers several strategic advantages: Enables outpatient and at-home administration after initial supervision Reduces dependency on infusion centers compared to intravenous biologics Supports long-term chronic disease management Aligns with specialty pharmacy distribution models Because it is a targeted IL-23 inhibitor, Tremfya competes within the high-value biologics segment of immune-mediated therapies. The injectable biologic category is characterized by: Premium pricing structures Strong payer management and prior authorization controls High patient lifetime value due to chronic treatment cycles Emphasis on adherence programs and patient support services Market growth within this segment is supported by continued physician preference for precision immunomodulation and improved safety profiles relative to broader immunosuppressive therapies. Application Insights: Plaque Psoriasis Plaque psoriasis represents the primary and most established indication for Tremfya. Within this segment, Tremfya is positioned for patients with moderate-to-severe disease requiring systemic therapy. Market dynamics in this application are influenced by: Long-term disease control needs Demand for sustained skin clearance Increasing patient expectations for high response rates Competitive biologic switching trends The plaque psoriasis segment contributes a substantial share of total market revenue due to the large eligible patient pool and chronic treatment duration. As treatment goals evolve toward complete or near-complete skin clearance, IL-23 inhibitors have strengthened their clinical positioning. Growth in this segment is driven by: Earlier biologic initiation in treatment algorithms Expanded reimbursement coverage Real-world evidence supporting durability of response Psoriatic Arthritis Psoriatic arthritis represents a strategically important expansion segment. In this application, Tremfya addresses both joint inflammation and skin manifestations, positioning it within rheumatology prescribing networks. Compared to plaque psoriasis, this segment involves: Multidisciplinary management (dermatology and rheumatology overlap) Greater emphasis on functional improvement and structural damage prevention Competitive positioning against TNF inhibitors and other biologics Market growth in psoriatic arthritis is supported by increasing diagnosis rates and earlier biologic intervention to prevent long-term disability. As rheumatologists integrate IL-23 pathway targeting into treatment algorithms, this segment is expected to contribute incremental revenue diversification beyond dermatology-focused prescribing. Pipeline Applications (Crohn’s Disease & Ulcerative Colitis – Under Study) Pipeline indications in inflammatory bowel diseases represent forward-looking growth drivers. While still under clinical development, these applications expand Tremfya’s relevance into gastroenterology. If successfully commercialized, this segment could: Broaden the addressable patient population Increase cross-specialty adoption Strengthen lifecycle management strategies Extend product exclusivity value The inflammatory bowel disease space is highly competitive, but IL-23 inhibition has demonstrated mechanistic relevance. Entry into these indications would significantly shift the product’s revenue mix and reduce reliance on dermatology-dominant demand. Distribution Channel Insights: Hospital Pharmacies Hospital pharmacies account for a meaningful portion of initial therapy dispensing, particularly during therapy initiation and specialist-driven treatment transitions. Their importance stems from: Integration with specialist prescribing workflows Handling of biologic cold-chain logistics Insurance verification and benefit investigation support Management of complex patient onboarding Hospital-linked systems are particularly relevant for newly diagnosed moderate-to-severe patients and those transitioning from other biologics. Specialty Clinics Specialty clinics — particularly dermatology and rheumatology centers — represent a critical channel in Tremfya’s market ecosystem. These clinics: Serve as primary prescribing hubs Provide injection training and patient education Coordinate with specialty pharmacies for fulfillment Drive switching decisions between biologics Because Tremfya competes in a specialized therapeutic category, prescribing concentration within specialty practices reinforces targeted commercial strategies and focused physician engagement models. Retail & Specialty Pharmacies Retail and specialty pharmacies play a central role in maintenance therapy distribution. Given Tremfya’s subcutaneous format, ongoing refills are commonly managed through specialty pharmacy networks rather than traditional retail dispensing alone. Key structural characteristics of this channel include: Cold-chain management capabilities Patient adherence monitoring Reimbursement navigation support Home delivery services Specialty pharmacies contribute significantly to patient retention and long-term therapy continuation, directly influencing lifetime treatment value. Online Pharmacies Online pharmacy distribution is gradually emerging as a convenience-driven fulfillment pathway. While biologic therapies require controlled storage and handling, digital ordering platforms integrated with specialty pharmacy services are gaining traction. Growth in this channel is supported by: Increased digital health adoption Patient preference for home-based care Remote consultation models Expanded tele-dermatology and tele-rheumatology services Although still secondary to specialty pharmacy channels, online fulfillment is expected to strengthen as chronic disease management becomes more digitally integrated. Segment Evolution Perspective The Tremfya (Guselkumab) Market reflects broader shifts in immune-mediated disease management: Movement toward precision biologics targeting specific inflammatory pathways Increased chronic therapy duration and patient retention focus Expansion beyond core dermatology into multi-specialty indications Distribution shift toward specialty and home-based fulfillment models While plaque psoriasis remains the foundational revenue segment, psoriatic arthritis and pipeline inflammatory bowel indications provide long-term expansion potential. Simultaneously, specialty pharmacy dominance and digital distribution integration are redefining how biologic therapies reach patients. Overall, the segmentation structure highlights a market driven by innovation in targeted immunology, specialty-led prescribing, and evolving healthcare delivery models that prioritize convenience, adherence, and sustained disease control. Market Segmentation And Forecast Scope The Tremfya (Guselkumab) market can be segmented across multiple dimensions: product type, application, distribution channel, and geography. Each segment reflects how healthcare systems and prescribers adopt biologics within immunology. By product type, Tremfya is primarily positioned as a biologic injectable therapy. Its differentiation comes from a subcutaneous formulation delivered every eight weeks after loading doses. This less frequent dosing is attractive compared to older biologics, which require more frequent administration. Pipeline developments are being monitored closely, but currently the injectable format remains the only commercialized version. By application, the two core indications driving Tremfya’s market share are plaque psoriasis and psoriatic arthritis. Plaque psoriasis remains the larger segment, accounting for over half of Tremfya’s global use in 2024. Psoriatic arthritis is the second major driver, with adoption rising as rheumatologists increasingly shift to targeted biologics for patients with moderate to severe disease activity. Ongoing trials in Crohn’s disease and ulcerative colitis are expected to expand Tremfya’s application base later in the decade, which could diversify revenue streams and enhance its long-term positioning. By distribution channel, Tremfya is dispensed mainly through hospital pharmacies, specialty pharmacies, and retail drug stores. Hospital and specialty pharmacies dominate in developed markets where biologics require tight handling and reimbursement coordination. Retail pharmacies are gaining share in markets with stronger specialty drug programs, while online pharmacy platforms are slowly emerging as a secondary channel in some regions, particularly in Asia-Pacific. By region, the Tremfya market covers North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America leads due to high diagnosis rates, strong reimbursement, and specialist availability. Europe follows closely, supported by universal healthcare access and strong adoption in countries like Germany and the UK. Asia-Pacific is expected to record the fastest growth, driven by rising biologics adoption in Japan, South Korea, China, and India. Latin America and the Middle East and Africa remain smaller markets but are gaining traction as public and private healthcare systems expand their immunology drug portfolios. Scope-wise, this segmentation demonstrates that Tremfya’s market growth is not only driven by its two primary indications but also by future opportunities in gastrointestinal diseases, expanding retail access points, and faster biologics penetration in emerging economies. Market Trends And Innovation Landscape The Tremfya (Guselkumab) market is evolving alongside broader shifts in the immunology and biologics landscape. Between 2024 and 2030, innovation is likely to center on three core areas: clinical expansion, technology-driven treatment support, and competitive differentiation. One of the most prominent strategic shifts around Tremfya is the pursuit of broader therapeutic indications beyond dermatology and rheumatology. While the drug has already established a strong foothold in plaque psoriasis and psoriatic arthritis, ongoing clinical programs are evaluating its potential in Crohn’s disease and ulcerative colitis. These gastrointestinal indications represent a sizable expansion opportunity. If clinical outcomes are favorable, Tremfya could access a substantially larger inflammatory bowel disease population. More importantly, label expansion would strengthen its competitive position within the IL-23 inhibitor class, where multiple players are actively targeting GI pathways. In immunology, breadth of indication often translates directly into payer leverage and physician familiarity. Expanding into gastroenterology would allow Janssen to deepen prescriber relationships and diversify revenue streams beyond dermatology-centric markets. Another defining development is the refinement of dosing schedules and adherence strategies. Tremfya already benefits from an every-eight-week maintenance regimen, a meaningful advantage compared to older biologics that require more frequent injections. Reduced dosing frequency lowers treatment fatigue and simplifies long-term disease management. However, convenience alone is no longer enough. Companies are now investing in structured patient support programs, digital adherence platforms, remote monitoring tools, and at-home injection services. These initiatives are not cosmetic add-ons. They directly influence treatment persistence rates, which in turn shape payer cost-effectiveness models. Higher persistence means fewer flares, fewer switches, and more predictable outcomes. In value-based healthcare systems, that translates into stronger reimbursement positioning. From a technological and evidence-generation standpoint, real-world evidence platforms and digital health integration are gaining strategic importance. Health systems and insurers increasingly demand long-term safety and comparative effectiveness data outside tightly controlled clinical trial settings. To address this, Janssen and competing manufacturers are investing in: Patient registries across multiple geographies AI-enabled outcome tracking systems Post-marketing surveillance databases focused on adverse events and durability metrics These tools help demonstrate sustained benefit, reduced hospitalization rates, and long-term economic value. Over time, such evidence can directly influence formulary tier placement and reimbursement negotiations. Competition within the IL-23 inhibitor segment continues to intensify. Rivals such as risankizumab and tildrakizumab are actively expanding indication portfolios and sharpening their clinical positioning. Skyrizi, in particular, has pursued an aggressive multi-indication expansion strategy, creating a competitive race around label breadth and lifecycle management. This environment forces Tremfya’s strategy to remain agile. Incremental formulation refinements must be balanced with bold expansion initiatives to maintain differentiation. Standing still in immunology is rarely an option. Another macro trend shaping the landscape is the growing acceptance of biosimilars in inflammatory diseases. While Tremfya itself does not yet face biosimilar competition, the entry of biosimilars for legacy biologics such as Humira has fundamentally shifted payer expectations. The long-term implication is clear. Premium biologics will increasingly need to justify pricing through superior durability, expanded indications, improved adherence infrastructure, or bundled patient services. Cost alone will not sustain market share. Demonstrated value will. In summary, the innovation ecosystem surrounding Tremfya now extends beyond molecule efficacy. It encompasses indication expansion, adherence optimization, real-world data generation, and payer economics. Janssen’s ability to integrate scientific progress with patient experience and reimbursement strategy will likely determine Tremfya’s competitive trajectory through 2030. Competitive Intelligence And Benchmarking The Tremfya (Guselkumab) market sits within a highly competitive biologics class, where innovation and speed to indication expansion are key determinants of market share. Janssen Pharmaceuticals, through its parent Johnson & Johnson, holds the commercial rights to Tremfya and has built a strong positioning strategy based on differentiated dosing, durable response rates, and expanding clinical evidence. Benchmarking Tremfya against other IL-23 inhibitors reveals both strengths and vulnerabilities. Skyrizi , marketed by AbbVie, is the most formidable competitor. It has gained rapid adoption due to aggressive clinical expansion, particularly in Crohn’s disease and ulcerative colitis. Skyrizi’s multi-indication strategy gives it broader physician visibility across specialties, making it a benchmark for market penetration. In contrast, Tremfya’s current approvals remain limited to psoriasis and psoriatic arthritis, though ongoing trials could help narrow this gap. Ilumya , developed by Sun Pharma, represents another player in the IL-23 space. While Ilumya’s adoption has been more modest, it competes on pricing and accessibility in certain markets, particularly in Asia-Pacific. This pricing dynamic highlights a pressure point for Tremfya as payers continue to weigh efficacy against cost, especially in emerging regions. Stelara, Janssen’s own IL-12/23 inhibitor, still holds a notable market presence, especially in gastrointestinal diseases. However, Janssen is carefully managing the transition from Stelara to Tremfya, aiming to move patients toward the more selective IL-23 mechanism that aligns with future growth. This internal portfolio balancing act is critical for Johnson & Johnson to defend overall market share against external competitors. Beyond IL-23 inhibitors, the competitive field includes IL-17 blockers such as secukinumab (Novartis) and ixekizumab (Eli Lilly), as well as TNF inhibitors that remain entrenched in some treatment pathways. Although these drugs represent older classes, they continue to hold formulary positions, often as first-line biologics due to lower costs and long-standing safety records. Tremfya must therefore compete not only within its immediate class but also across adjacent biologics with entrenched market access. Strategically, Janssen’s approach centers on lifecycle management. This includes broadening Tremfya’s indications, investing in long-term safety data, and strengthening payer partnerships. At the same time, competitor strategies focus on expanding market share through aggressive pricing, broader indication portfolios, and enhanced patient support programs. The competitive intelligence picture underscores a fundamental reality: Tremfya has strong differentiation today, but maintaining leadership requires constant adaptation. Its benchmarking against AbbVie’s Skyrizi , Sun Pharma’s Ilumya , and legacy biologics like Stelara shows both the opportunity and the urgency of expanding its therapeutic footprint before biosimilars and new mechanisms disrupt the landscape further. Regional Landscape And Adoption Outlook The adoption of Tremfya varies significantly across regions, shaped by healthcare infrastructure, reimbursement systems, physician practices, and patient awareness. Between 2024 and 2030, regional dynamics will define where growth accelerates fastest and where barriers remain. In North America, Tremfya has established a leading presence, with the United States accounting for the largest share of prescriptions. High psoriasis prevalence, strong specialist networks, and favorable reimbursement policies underpin adoption. The presence of established specialty pharmacy channels and patient assistance programs further supports adherence. In Canada, public health coverage has expanded biologic access, though cost-containment pressures remain. North America will likely continue to hold the largest share of the Tremfya market through 2030, driven by both psoriasis and psoriatic arthritis patients. Europe is another stronghold, particularly in Germany, the UK, and the Nordics, where biologics adoption is well integrated into standard treatment pathways. The European Medicines Agency has provided regulatory momentum with label expansions, while national health systems are gradually widening reimbursement. However, budget constraints and increasing pressure to evaluate cost-effectiveness mean that Tremfya competes closely with other IL-23 inhibitors and older biologics that remain in formularies. Southern and Eastern Europe lag somewhat in adoption due to more limited funding and slower guideline updates. Asia-Pacific is expected to record the fastest growth. Countries like Japan and South Korea are early adopters of advanced biologics, with streamlined reimbursement frameworks and strong physician confidence. China and India, with their large psoriasis patient bases, are beginning to scale up biologics access as healthcare infrastructure expands. However, affordability remains a challenge in many parts of the region, and payer negotiations will play a decisive role in future uptake. Partnerships with local distributors and governments will be essential for Janssen to expand Tremfya’s footprint here. Latin America is showing gradual adoption, with Brazil and Mexico leading regional demand. In these markets, public-private partnerships and specialty programs are enabling access to biologics, though out-of-pocket costs remain high for many patients. Argentina and Colombia also offer opportunities, but regulatory and pricing complexities can delay widespread adoption. The Middle East and Africa currently represent the smallest share of the market. Wealthier Gulf countries, particularly Saudi Arabia and the UAE, are introducing Tremfya into advanced hospital networks, but broader adoption across Africa is constrained by infrastructure gaps and limited reimbursement capacity. Over time, donor-funded programs and collaborations with private hospitals may open growth opportunities in underserved populations. Overall, regional analysis highlights a two-speed market. North America and Europe remain the most mature with entrenched adoption, while Asia-Pacific and Latin America offer higher growth rates due to expanding healthcare access. For Tremfya to maximize its global footprint, Janssen must balance defending share in established regions with aggressively pursuing white space in emerging markets. End-User Dynamics And Use Case Tremfya adoption is shaped by the types of healthcare providers that prescribe and manage biologic therapies. Each end-user group approaches the drug differently, based on patient volume, treatment protocols, and financial considerations. Hospital pharmacies remain the most common dispensing point in developed markets. Large hospitals with dermatology and rheumatology departments typically handle biologic prescriptions, supported by in-house specialty pharmacies that coordinate prior authorizations and patient monitoring. These institutions value Tremfya’s long dosing interval, which reduces patient visits and administrative burden compared to older biologics. Specialty clinics, particularly dermatology and rheumatology practices, play a central role in adoption. In the U.S. and parts of Europe, independent specialist clinics account for a significant share of prescriptions. These providers are often early adopters of new therapies, guided by clinical trial evidence and updated guidelines. Their prescribing decisions are heavily influenced by payer formularies but also by the perceived ease of patient adherence. Tremfya’s every-eight-week schedule and strong safety profile are appealing in this context. Retail and specialty pharmacies are increasingly important in distribution, especially in markets where patient access is shifting outside of hospital systems. Programs that enable home delivery and nurse-assisted at-home injections are gaining traction. This shift reflects a broader healthcare trend of decentralizing specialty drug delivery to improve patient convenience and reduce system costs. Ambulatory surgical centers play a smaller role, but in cases where biologics are started in perioperative settings, they may contribute to initiation volumes. However, ongoing maintenance therapy generally transitions to hospitals or outpatient clinics. A practical use case illustrates these dynamics. In a U.S. community dermatology clinic, physicians introduced Tremfya as a second-line option for patients who had not responded well to topical treatments or older biologics. The clinic integrated a digital patient support platform that reminded patients of injection schedules and tracked symptom improvements. Within one year , patient adherence improved by nearly 20 percent, and the clinic reported fewer treatment interruptions. This not only improved patient outcomes but also reduced payer disputes over therapy persistence. These examples show that Tremfya’s value is experienced differently across end-user segments. Hospitals prioritize streamlined administration, specialty clinics focus on clinical effectiveness and patient adherence, and pharmacies emphasize logistics and affordability. For Janssen, aligning engagement strategies with each end-user group will remain essential to sustaining Tremfya’s competitive position. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) In 2023, Janssen secured expanded FDA approval for Tremfya in active psoriatic arthritis, strengthening its positioning in rheumatology. Phase III trial data released in 2023 showed promising results for Tremfya in Crohn’s disease, signaling potential entry into gastrointestinal indications. In 2024, the European Medicines Agency updated its label to include new long-term safety data, which supported broader use in plaque psoriasis patients. Janssen has expanded patient access programs across North America and Europe, focusing on co-pay assistance and digital adherence platforms. Opportunities Expanding indications into Crohn’s disease and ulcerative colitis could open significant new patient populations and diversify revenue. Rising biologics adoption in Asia-Pacific and Latin America offers growth potential as healthcare access and reimbursement frameworks improve. Increasing reliance on real-world evidence and digital monitoring platforms creates opportunities to strengthen payer negotiations and demonstrate long-term cost-effectiveness. Restraints Intense competition from other IL-23 inhibitors such as risankizumab and tildrakizumab, as well as IL-17 and TNF inhibitors that remain entrenched in formularies. Pricing pressures from payers and governments, especially as biosimilars of older biologics reset expectations for cost-effectiveness. 7.1. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 3.1 Billion Revenue Forecast in 2030 USD 5.8 Billion Overall Growth Rate CAGR of 9.1% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Product Type, By Application, By Distribution Channel, By Geography By Product Type Injectable Biologic (subcutaneous) By Application Plaque Psoriasis, Psoriatic Arthritis, Pipeline (Crohn’s, Ulcerative Colitis – under study) By Distribution Channel Hospital Pharmacies, Specialty Clinics, Retail & Specialty Pharmacies, Online Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, Germany, UK, France, China, India, Japan, Brazil, Saudi Arabia, South Africa Market Drivers - Growing autoimmune disease burden - Expanding biologics reimbursement - Advancements in IL-23 inhibitor pipeline Customization Option Available upon request Frequently Asked Question About This Report Q1: How big is the Tremfya market? A1: The global Tremfya market is valued at USD 3.1 billion in 2024. Q2: What is the CAGR for the Tremfya market during the forecast period? A2: The market is expected to grow at a CAGR of 9.1% between 2024 and 2030. Q3: Who are the major players in the Tremfya market? A3: The leading players include Janssen Pharmaceuticals (Johnson & Johnson), AbbVie, Sun Pharma, Novartis, and Eli Lilly. Q4: Which region dominates the Tremfya market? A4: North America leads the market due to strong reimbursement, specialist networks, and early adoption of biologics. Q5: What factors are driving the growth of the Tremfya market? A5: Growth is driven by increasing prevalence of autoimmune diseases, rising adoption of biologics, expanding reimbursement coverage, and ongoing pipeline expansion into gastrointestinal indications. Table of Contents – Global Tremfya (Guselkumab) Market Report (2024–2030) Executive Summary Market Overview Market Attractiveness by Product Type, Application, Distribution Channel, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2019–2030) Summary of Market Segmentation by Product Type, Application, Distribution Channel, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Application, and Distribution Channel Investment Opportunities in the Tremfya (Guselkumab) Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Behavioral and Regulatory Factors Pricing and Reimbursement Landscape for Biologics Global Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type Injectable Biologic (Subcutaneous Formulation) Market Analysis by Application Plaque Psoriasis Psoriatic Arthritis Pipeline Indications (Crohn’s Disease, Ulcerative Colitis – under clinical evaluation) Market Analysis by Distribution Channel Hospital Pharmacies Specialty Clinics Retail & Specialty Pharmacies Online Pharmacies Market Analysis by Region North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type, Application, and Distribution Channel Country-Level Breakdown: United States, Canada, Mexico Europe Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type, Application, and Distribution Channel Country-Level Breakdown: Germany, United Kingdom, France, Italy, Spain, Rest of Europe Asia-Pacific Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type, Application, and Distribution Channel Country-Level Breakdown: China, India, Japan, South Korea, Rest of Asia-Pacific Latin America Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type, Application, and Distribution Channel Country-Level Breakdown: Brazil, Argentina, Rest of Latin America Middle East & Africa Tremfya (Guselkumab) Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Product Type, Application, and Distribution Channel Country-Level Breakdown: GCC Countries, South Africa, Rest of Middle East & Africa Key Players and Competitive Analysis Janssen Pharmaceuticals (Johnson & Johnson) AbbVie Sun Pharma Novartis Eli Lilly Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Application, Distribution Channel, and Region (2024–2030) Regional Market Breakdown by Segment Type (2024–2030) List of Figures Market Drivers, Challenges, and Opportunities Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Application, and Distribution Channel (2024 vs. 2030)